Governance frameworks for cross functional IP and regulatory committees Governance frameworks for cross functional IP and regulatory committees Context The development and approval of biosimilars involve intricate regulatory and intellectual property (IP) landscapes, especially within the frameworks provided by the Biologics Control Act and the Biosimilars User Fee Act (BPCIA) in the United States. As biosimilars continue to gain traction in global markets, the governance frameworks established for cross-functional committees become pivotal. These committees must effectively navigate the interactions between regulatory affairs, clinical development, commercial strategy, and IP management. Legal/Regulatory Basis In the U.S., the BPCIA serves as the cornerstone…

Integrating payer and pricing strategy with IP and exclusivity timelines Integrating Payer and Pricing Strategy with IP and Exclusivity Timelines Context The development of biosimilars represents a significant evolution in the biotech and pharmaceutical landscape. With biosimilars poised to offer competitive alternatives in the marketplace, understanding the regulatory, intellectual property (IP), and exclusivity frameworks is essential for ensuring both market access and profitability. This guide aims to outline the regulatory affairs context and provide a comprehensive overview of the key factors influencing the biosimilar patent landscape, focusing on the United States (US), the European Union (EU), and the United Kingdom…

Risk management for at risk biosimilar launches in the United States Risk management for at risk biosimilar launches in the United States The development and approval pathways for biosimilars present unique regulatory challenges, particularly concerning patent issues and market exclusivity. This article provides a comprehensive framework for navigating the complexities of biosimilar launches, specifically focusing on the patent dance, attractiveness of the Orange Book and Purple Book, and effective risk management strategies. Regulatory Context Biosimilars are biologic products highly similar to an already FDA-approved reference product. The approval of biosimilars in the United States is primarily governed by the Biologics…

Tools and databases for tracking patents, exclusivity and Purple Book changes Tools and databases for tracking patents, exclusivity and Purple Book changes Biosimilar development presents unique challenges related to intellectual property rights, regulatory compliance, and market access strategies. Key elements such as the Biosimilar Product Competition and Innovation Act (BPCIA), the Orange Book, and the Purple Book play critical roles in guiding development and commercial strategies. This regulatory explainer manual provides an in-depth understanding of the biosimilar patent dance, exclusivity, and strategies for leveraging the Orange and Purple Books, tailored for regulatory affairs professionals. Context Biosimilars are biological products that…

Lessons Learned from First Wave Biosimilar Launches on IP and LOE Strategy Lessons Learned from First Wave Biosimilar Launches on IP and LOE Strategy Introduction to Biosimilar Development Biosimilars are biological medicinal products that are highly similar to already authorized reference biological medicines. The development of biosimilars presents unique challenges and considerations, particularly in the realm of Intellectual Property (IP) strategy and loss of exclusivity (LOE) planning. The complexities surrounding these products necessitate a comprehensive understanding of regulatory frameworks and strategies to navigate the intricacies of the biosimilar patent dance, as well as to effectively leverage the Orange Book and…